NCT03737994 2026-03-18
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
46 trialsNCT03811002 2026-03-18
Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT04222972 2026-03-05
AcceleRET-Lung
Hoffmann-La Roche
Phase 3 Terminated
NCT03132532 2025-11-25
Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
Mayo Clinic
Phase 2 Completed
NCT05014815 2025-09-16
Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer
BeiGene
Phase 2 Completed
NCT02262325 2025-06-12
Hypofractionated Boost Before Chemoradiation for Patients With Stage II-III Non-small Cell Lung Cancer Unsuitable for Surgery
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT06094296 2025-04-16
A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb
Phase 2 Terminated
NCT04786964 2025-04-02
CONTERNO
Checkpoint Therapeutics, Inc.
Phase 3 Terminated
NCT02489903 2025-03-17
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
EpicentRx, Inc.
Phase 2 Completed
NCT01828099 2025-01-16
LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer
Novartis
Phase 3 Completed
NCT04364048 2024-12-20
Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer
Hoosier Cancer Research Network
Phase 2 Terminated
NCT00791154 2024-08-23
SCLC
NantCell, Inc.
Phase 1/2 Terminated
NCT00617656 2024-01-30
BREC
Spanish Lung Cancer Group
Phase 3 Terminated
NCT02709720 2024-01-11
NORA
Spanish Lung Cancer Group
Phase 2 Completed
NCT04971187 2023-08-01
Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT04372927 2023-06-13
ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy
University of Washington
Phase 2 Terminated
NCT00632853 2023-06-12
Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide
Alliance for Clinical Trials in Oncology
Phase 3 Unknown
NCT00301808 2023-05-06
Cisplatin, Pemetrexed Disodium, and Radiation Therapy Followed by Docetaxel in Treating Patients With Stage III Non-Small Cell Lung Cancer
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT02768558 2021-06-02
Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC
RTOG Foundation, Inc.
Phase 3 Terminated
NCT01820754 2021-02-26
TOP1201 IPI
Duke University
Phase 2 Completed
NCT00794417 2020-12-10
A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Carcinoma
Regeneron Pharmaceuticals
Phase 1/2 Terminated
NCT00832117 2020-10-28
Phase I Combination Ixabepilone + Cisplatin
R-Pharm
Phase 1 Completed
NCT00589056 2020-04-24
Nelfinavir, Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
Abramson Cancer Center at Penn Medicine
Phase 1/2 Completed
NCT00792701 2020-03-06
S0720: Adjuvant Therapy Based on Gene Expression in Stage IA and IB Non-Small Cell Lung Cancer
SWOG Cancer Research Network
Phase 2 Completed
NCT01232452 2019-09-20
A Study in Non-Small Cell Lung Cancer
Eli Lilly and Company
Phase 2 Completed
NCT01160744 2019-09-13
A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)
Eli Lilly and Company
Phase 2 Completed
NCT03348904 2019-06-13
Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer
Incyte Corporation
Phase 3 Terminated
NCT00554463 2019-05-29
G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer
Radiation Therapy Oncology Group
Phase 2 Completed
NCT01443078 2018-08-09
Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00045162 2018-07-31
S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer
SWOG Cancer Research Network
Phase 3 Completed
NCT00577707 2018-01-10
Erlotinib and Chemotherapy for Patients With Stage IB-IIIA NSCLC With EGFR Mutations (ECON)
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00066222 2017-12-22
Cisplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
Radiation Therapy Oncology Group
Phase 2 Completed
NCT00248495 2017-07-12
Pemetrexed Disodium and Cisplatin in Treating Patients Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
Roswell Park Cancer Institute
Phase 2 Completed
NCT00227539 2017-05-09
Positron Emission Tomography in Predicting Response in Patients Who Are Undergoing Treatment With Pemetrexed Disodium and Cisplatin With or Without Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
University of Washington
Phase 2 Completed
NCT01109524 2015-12-24
Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00530634 2015-10-29
Surgery, Gemcitabine, Cisplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Non-Small Cell Lung Cancer
City of Hope Medical Center
Phase 2 Terminated
NCT01222572 2015-06-04
Stereotactic Boost for Locally Advanced Non-Small Cell Lung Cancer
Dana-Farber Cancer Institute
Phase 1/2 Terminated
NCT01209520 2015-02-24
Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy
University of Miami
Phase NA Completed
NCT00726986 2014-11-19
Sorafenib, Cisplatin, and Etoposide in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Case Comprehensive Cancer Center
Phase 2 Terminated
NCT02127372 2014-09-15
Maximum Tolerated Dose, Safety and Efficacy of Docetaxel / Cisplatin + STI571
Duke University
Phase 1/2 Terminated
NCT00148798 2014-06-25
FLEX
Merck KGaA, Darmstadt, Germany
Phase 3 Completed
NCT00101907 2014-03-20
Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced Cancer
Amgen
Phase 1 Terminated
NCT00062439 2013-11-25
S0220: Chemoradiotherapy Followed By Surgery and Docetaxel in Treating Patients With Pancoast Tumors
SWOG Cancer Research Network
Phase 2 Completed
NCT00413283 2013-10-24
Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)
Amgen
Phase 2 Completed
NCT00113386 2013-06-28
Cisplatin and Docetaxel With or Without Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Newly Diagnosed Stage III Non-Small Cell Lung Cancer
Radiation Therapy Oncology Group
Phase 3 Terminated
NCT00735904 2013-01-03
Trial Of AG-013736, Cisplatin, And Gemcitabine For Patients With Squamous Non-Small Cell Lung Cancer
Pfizer
Phase 2 Completed